WEBSITE BSE:524606 NSE: BERYL DRUGS Inc. Year: 1993 Industry: Pharmaceuticals & Drugs My Bucket: Add Stock
Last updated: 11:12
No Notes Added Yet
Beryl Drugs Ltd is an Indian publicly listed pharmaceutical company incorporated on 24 August 1993 and headquartered in Indore, Madhya Pradesh. It operates primarily in the healthcare and pharmaceutical industry, manufacturing and marketing a wide range of branded and generic pharmaceutical formulations that include intravenous (I.V.) fluids, small volume injectables, eye and ear drops, veterinary medicines, and other injectable products. The company began by acquiring the business of an existing firm and has since developed a nationwide sa...Read More
Beryl Drugs Ltd is an Indian publicly listed pharmaceutical company incorporated on 24 August 1993 and headquartered in Indore, Madhya Pradesh. It operates primarily in the healthcare and pharmaceutical industry, manufacturing and marketing a wide range of branded and generic pharmaceutical formulations that include intravenous (I.V.) fluids, small volume injectables, eye and ear drops, veterinary medicines, and other injectable products. The company began by acquiring the business of an existing firm and has since developed a nationwide sales and distribution network to serve domestic institutional and retail markets, with some exports. Over the years, Beryl Drugs has built manufacturing capabilities compliant with recognised quality standards, focusing on producing dosage forms such as liquid and dry powder injectables and other formulations while emphasizing quality management and production infrastructure. Its operations also include research and development activities and contract manufacturing services, reflecting efforts to expand its product offerings and technical competencies. Listed as a small‑cap company on Indian stock exchanges, Beryl Drugs’ financial and market performance reflects the dynamics of the competitive pharmaceutical sector, with modest revenue and market capitalization relative to larger peers. The company’s leadership is headed by industry executives including Sudhir Sethi as Chairman, and its strategy centers on maintaining product quality, expanding market reach, and leveraging its manufacturing base to sustain growth in the pharmaceuticals segment. ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹11 Cr.
Stock P/E 19.1
P/B 1.2
Current Price ₹21.8
Book Value ₹ 18.3
Face Value 10
52W High ₹30
Dividend Yield 0%
52W Low ₹ 15.9
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 8 | 8 | 3 | 6 | 6 | 5 | 5 | 5 | 5 | 4 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income | 8 | 8 | 3 | 6 | 6 | 5 | 5 | 5 | 5 | 4 |
| Total Expenditure | 7 | 7 | 3 | 5 | 5 | 5 | 5 | 4 | 4 | 4 |
| Operating Profit | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | -0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 |
| Provision for Tax | 0 | 0 | -0 | 0 | 0 | 0 | -0 | 0 | 0 | -0 |
| Profit After Tax | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 |
| Adjustments | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 0 |
| Profit After Adjustments | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 |
| Adjusted Earnings Per Share | 0.5 | 0.6 | -0.7 | 0.7 | 0 | 0.1 | 0.3 | 0 | 0 | -0.3 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 13 | 13 | 11 | 15 | 13 | 13 | 14 | 15 | 27 | 27 | 21 | 19 |
| Other Income | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| Total Income | 13 | 13 | 11 | 16 | 13 | 13 | 14 | 15 | 27 | 27 | 23 | 19 |
| Total Expenditure | 13 | 13 | 10 | 14 | 12 | 12 | 13 | 14 | 25 | 25 | 20 | 17 |
| Operating Profit | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 2 | 3 | 3 | 2 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Depreciation | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 0 | 0 | 0 | 1 | 1 | 0 | 0 | -1 | 1 | 1 | 1 | -1 |
| Provision for Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 |
| Profit After Tax | 0 | 0 | 0 | 1 | 1 | 0 | 0 | -1 | 1 | 1 | 1 | 0 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 0 | 0 | 0 | 1 | 1 | 0 | 0 | -1 | 1 | 1 | 1 | 0 |
| Adjusted Earnings Per Share | 0.2 | 0.3 | 0.2 | 2 | 1.2 | 0.1 | 0.5 | -1.3 | 1.5 | 1.5 | 1.1 | 0 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | -22% | 12% | 10% | 5% |
| Operating Profit CAGR | 0% | 44% | 25% | 12% |
| PAT CAGR | 0% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 11% | 17% | 27% | -5% |
| ROE Average | 6% | 8% | 4% | 4% |
| ROCE Average | 10% | 11% | 7% | 7% |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 6 | 7 | 7 | 7 | 8 | 8 | 8 | 7 | 8 | 9 | 10 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 2 | 3 | 2 | 2 |
| Other Non-Current Liabilities | -0 | -0 | -0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | 4 | 3 | 4 | 4 | 6 | 7 | 8 | 9 | 6 | 6 | 4 |
| Total Liabilities | 11 | 10 | 11 | 11 | 14 | 17 | 19 | 18 | 17 | 18 | 16 |
| Fixed Assets | 2 | 2 | 2 | 2 | 2 | 8 | 7 | 6 | 6 | 6 | 6 |
| Other Non-Current Assets | 2 | 1 | 1 | 2 | 7 | 1 | 1 | 1 | 1 | 1 | 1 |
| Total Current Assets | 6 | 6 | 7 | 7 | 5 | 8 | 10 | 10 | 10 | 10 | 9 |
| Total Assets | 11 | 10 | 11 | 11 | 14 | 17 | 19 | 18 | 17 | 18 | 16 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash Flow from Operating Activities | 1 | -0 | 0 | -0 | 3 | 0 | 0 | -0 | 2 | 1 | 3 |
| Cash Flow from Investing Activities | 0 | 0 | 0 | -0 | -5 | -2 | 0 | 1 | -1 | -1 | -0 |
| Cash Flow from Financing Activities | -0 | -0 | -0 | -0 | 2 | 2 | -1 | -0 | -1 | 0 | -2 |
| Net Cash Inflow / Outflow | 1 | -0 | 0 | -0 | -0 | 0 | 0 | -0 | 0 | -0 | 1 |
| Closing Cash & Cash Equivalent | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| # | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 0.17 | 0.33 | 0.23 | 1.96 | 1.16 | 0.09 | 0.47 | -1.3 | 1.51 | 1.52 | 1.14 |
| CEPS(Rs) | 1.18 | 1.14 | 0.97 | 2.61 | 1.8 | 1.39 | 2.98 | 0.84 | 3.12 | 3.88 | 3.6 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 12.76 | 13.09 | 13.35 | 13.1 | 14.8 | 14.99 | 15.59 | 14.34 | 15.86 | 17.55 | 18.7 |
| Core EBITDA Margin(%) | 5.17 | 3.66 | 4.32 | 6.8 | 7.89 | 7.07 | 10.28 | 2.95 | 7.39 | 8.24 | 4.73 |
| EBIT Margin(%) | 2.92 | 3.38 | 3.3 | 9.19 | 7.27 | 3.74 | 5.77 | -3.36 | 5.4 | 5.55 | 6.62 |
| Pre Tax Margin(%) | 1 | 1.8 | 1.49 | 8.33 | 6.14 | 1.23 | 2.47 | -6.51 | 3.66 | 3.78 | 4.09 |
| PAT Margin (%) | 0.62 | 1.22 | 1.02 | 6.49 | 4.56 | 0.37 | 1.7 | -4.51 | 2.85 | 2.88 | 2.74 |
| Cash Profit Margin (%) | 4.41 | 4.23 | 4.32 | 8.65 | 7.06 | 5.52 | 10.74 | 2.93 | 5.88 | 7.37 | 8.63 |
| ROA(%) | 0.83 | 1.62 | 1.11 | 9.08 | 4.67 | 0.31 | 1.35 | -3.63 | 4.36 | 4.37 | 3.43 |
| ROE(%) | 1.31 | 2.54 | 1.74 | 14.8 | 8.35 | 0.63 | 3.09 | -8.68 | 10 | 9.07 | 6.3 |
| ROCE(%) | 4.92 | 5.55 | 4.48 | 16.88 | 9.96 | 4.05 | 6.28 | -3.82 | 11.51 | 11.14 | 10.15 |
| Receivable days | 83.82 | 96.75 | 113.65 | 100.48 | 116.36 | 98.14 | 103.53 | 112.34 | 77.08 | 98.89 | 112.55 |
| Inventory Days | 38.97 | 40.75 | 67.47 | 48.17 | 29.73 | 27.36 | 44.37 | 65.57 | 27.39 | 15.8 | 27.3 |
| Payable days | 303.29 | 286.48 | 301.77 | 282.04 | 410.3 | 754.83 | 1005.85 | 1616.73 | 735.12 | 733.93 | 729.63 |
| PER(x) | 223.12 | 98.51 | 63.07 | 6.13 | 7.18 | 38.62 | 13.99 | 0 | 8.05 | 19.35 | 18.45 |
| Price/Book(x) | 2.91 | 2.47 | 1.09 | 0.92 | 0.56 | 0.24 | 0.42 | 0.73 | 0.77 | 1.67 | 1.13 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 1.49 | 1.33 | 0.76 | 0.49 | 0.57 | 0.52 | 0.57 | 0.68 | 0.38 | 0.74 | 0.66 |
| EV/Core EBITDA(x) | 21.61 | 20.08 | 10.99 | 4.28 | 5.83 | 5.88 | 4.91 | 16.64 | 4.48 | 7.39 | 5.27 |
| Net Sales Growth(%) | -9.09 | -1.33 | -16.15 | 37.75 | -14.42 | -1.12 | 9.97 | 3.62 | 84 | -0.53 | -20.89 |
| EBIT Growth(%) | -36.35 | 15.74 | -17.88 | 271.88 | -32.96 | -49.16 | 69.85 | -160.22 | 395.94 | 2.27 | -5.56 |
| PAT Growth(%) | -68.36 | 97.26 | -29.99 | 751.52 | -40.51 | -91.88 | 399.78 | -375.04 | 216.24 | 0.34 | -24.69 |
| EPS Growth(%) | -68.36 | 97.24 | -29.99 | 751.53 | -40.5 | -91.89 | 399.89 | -375.06 | 216.23 | 0.34 | -24.7 |
| Debt/Equity(x) | 0.27 | 0.25 | 0.25 | 0.22 | 0.43 | 0.69 | 0.65 | 0.73 | 0.56 | 0.57 | 0.43 |
| Current Ratio(x) | 1.52 | 1.83 | 1.73 | 1.79 | 0.98 | 1.13 | 1.24 | 1.23 | 1.63 | 1.72 | 2.08 |
| Quick Ratio(x) | 1.17 | 1.36 | 1.1 | 1.44 | 0.84 | 0.96 | 0.96 | 0.88 | 1.46 | 1.51 | 1.65 |
| Interest Cover(x) | 1.52 | 2.14 | 1.82 | 10.63 | 6.45 | 1.49 | 1.75 | -1.06 | 3.11 | 3.13 | 2.62 |
| Total Debt/Mcap(x) | 0.09 | 0.1 | 0.23 | 0.24 | 0.77 | 2.83 | 1.53 | 1 | 0.74 | 0.34 | 0.38 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 26.38 | 26.38 | 26.38 | 26.38 | 26.38 | 26.38 | 26.38 | 26.38 | 26.38 | 27.48 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 73.62 | 73.62 | 73.62 | 73.62 | 73.62 | 73.62 | 73.62 | 73.62 | 73.62 | 72.52 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.13 | 0.13 | 0.13 | 0.13 | 0.13 | 0.13 | 0.13 | 0.13 | 0.13 | 0.14 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.37 | 0.37 | 0.37 | 0.37 | 0.37 | 0.37 | 0.37 | 0.37 | 0.37 | 0.37 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 0.51 | 0.51 | 0.51 | 0.51 | 0.51 | 0.51 | 0.51 | 0.51 | 0.51 | 0.51 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
ChatGPT
Claude
Perplexity
